Nadja Hobel
Oberhaching, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Development and 10-year history of a biosimilar: the example of Binocrit®.
Journal: Therapeutic advances in medical oncology
Published: January 08, 2018
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience.
Journal: Drug design, development and therapy
Published: January 04, 2018
Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study .
Journal: Clinical nephrology
Published: November 24, 2017
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
Journal: European journal of haematology
Published: November 17, 2017
Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF study.
Journal: European journal of cancer care
Published: August 07, 2017
Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Journal: The oncologist
Published: July 24, 2017
Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.
Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: June 26, 2017
Ten years of clinical experience with biosimilar human growth hormone: a review of safety data.
Journal: Drug design, development and therapy
Published: May 30, 2017
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data.
Journal: Drug design, development and therapy
Published: May 30, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026